Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir

Antiviral Chemistry and Chemotherapy

Volumn 21, Issue 5, 2011, Pages 193-200

  Buys, Kristin K ^a   Jung, Kie Hoon ^a   Smee, Donald F ^a   Furuta, Yousuke ^b   Gowen, Brian B ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; RIBAVIRIN; VIRUS RNA; 6-FLUORO-3-HYDROXY-2-PYRAZINECARBOXAMIDE; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DOBRAVA VIRUS; DRUG EFFICACY; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HEMORRHAGIC FEVER WITH RENAL SYNDROME; IC 50; MAPORAL VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIN NOMBRE VIRUS; VERO CELL; VIRUS; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; CELL CULTURE; CERCOPITHECUS; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION; PATHOGENICITY;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; HANTAVIRUS; MICROBIAL SENSITIVITY TESTS; PYRAZINES; VERO CELLS; VIRUS REPLICATION;

EID: 80053329255     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1729     Document Type: Article

References (57)

1. Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis 1997; 3:95-104.
2. CDC. Outbreak of acute illness-southwestern United States,1993. MMWR Morb Mortal Wkly Rep 1993; 42:421-424.
3. Gonzalez Della Valle M, Edelstein A, Miguel S, et al. Andes virus associated with hantavirus pulmonary syndrome in northern Argentina and determination of the precise site of infection. Am J Trop Med Hyg 2002; 66:713-720.
4. Hjelle B, Lee SW, Song W, et al. Molecular linkage of hantavirus pulmonary syndrome to the white-footed mouse, Peromyscus leucopus: genetic characterization of the M genome of New York virus. J Virol 1995; 69:8137-8141.
5. Johnson AM, Bowen MD, Ksiazek TG, et al. Laguna Negra virus associated with HPS in western Paraguay and Bolivia. Virology 1997; 238:115-127.
6. Johnson AM, de Souza LT, Ferreira IB, et al. Genetic investigation of novel hantaviruses causing fatal HPS in Brazil. J Med Virol 1999; 59:527-535.
7. Khan AS, Gaviria M, Rollin PE, et al. Hantavirus pulmonary syndrome in Florida: association with the newly identified Black Creek Canal virus. Am J Med 1996; 100:46-48.
8. Khan AS, Spiropoulou CF, Morzunov S, et al. Fatal illness associated with a new hantavirus in Louisiana. J Med Virol 1995; 46:281-286.
9. Levis S, Morzunov SP, Rowe JE, et al. Genetic diversity and epidemiology of hantaviruses in Argentina. J Infect Dis 1998; 177:529-538.
10. López N, Padula P, Rossi C, Lazaro ME, Franze-Fernandez MT. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 1996; 220:223-226.
11. López N, Padula P, Rossi C, et al. Genetic characterization and phylogeny of Andes virus and variants from Argentina and Chile. Virus Res 1997; 50:77-84.
12. Morzunov SP, Feldmann H, Spiropoulou CF, et al. A newly recognized virus associated with a fatal case of hantavirus pulmonary syndrome in Louisiana. J Virol 1995; 69:1980-1983.
13. Nichol ST, Spiropoulou CF, Morzunov S, et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 1993; 262:914-917.
14. Padula P, Della Valle MG, Alai MG, Cortada P, Villagra M, Gianella A. Andes virus and first case report of Bermejo virus causing fatal pulmonary syndrome. Emerg Infect Dis 2002; 8:437-439.
15. Ravkov EV, Rollin PE, Ksiazek TG, Peters CJ, Nichol ST. Genetic and serologic analysis of Black Creek Canal virus and its association with human disease and Sigmodon hispidus infection. Virology 1995; 210:482-489.
16. Rhodes LV, III, Huang C, Sanchez AJ, et al. Hantavirus pulmonary syndrome associated with Monongahela virus, Pennsylvania. Emerg Infect Dis 2000; 6:616-621.
17. Vincent MJ, Quiroz E, Gracia F, et al. Hantavirus pulmonary syndrome in Panama: identification of novel hantaviruses and their likely reservoirs. Virology 2000; 277:14-19.
18. Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology 2001; 289:6-14.
19. Milazzo ML, Eyzaguirre EJ, Molina CP, Fulhorst CF. Maporal viral infection in the Syrian golden hamster: a model of hantavirus pulmonary syndrome. J Infect Dis 2002; 186:1390-1395.
20. Fulhorst CF, Cajimat MN, Utrera A, Milazzo ML, Duno GM. Maporal virus, a hantavirus associated with the fulvous pygmy rice rat (Oligoryzomys fulvescens) in western Venezuela. Virus Res 2004; 104:139-144.
21. Mackow ER, Gavrilovskaya IN. Cellular receptors and hantavirus pathogenesis. Curr Top Microbiol Immunol 2001; 256:91-115.
22. Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J Virol 1999; 73:3951-3959.
23. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. Beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A 1998; 95:7074-7079.
24. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002; 8:27-34.
25. Robinson SD, Reynolds LE, Wyder L, Hicklin DJ, Hodivala-Dilke KM. Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol 2004; 24:2108-2114.
26. Antic D, Kang CY, Spik K, Schmaljohn C, Vapalahti O, Vaheri A. Comparison of the deduced gene products of the L, M and S genome segments of hantaviruses. Virus Res 1992; 24:35-46.
27. Sen N, Sen A, Mackow ER. Degrons at the C terminus of the pathogenic but not the nonpathogenic hantavirus G1 tail direct proteasomal degradation. J Virol 2007; 81:4323-4330.
28. Geimonen E, LaMonica R, Springer K, Farooqui Y, Gavrilovskaya IN, Mackow ER. Hantavirus pulmonary syndrome-associated hantaviruses contain conserved and functional ITAM signaling elements. J Virol 2003; 77:1638-1643.
29. Geimonen E, Fernandez I, Gavrilovskaya IN, Mackow ER. Tyrosine residues direct the ubiquitination and degradation of the NY-1 hantavirus G1 cytoplasmic tail. J Virol 2003; 77:10760-10768.
30. Alff PJ, Gavrilovskaya IN, Gorbunova E, et al. The pathogenic NY-1 hantavirus G1 cytoplasmic tail inhibits RIG-I-and TBK-1-directed interferon responses. J Virol 2006; 80:9676-9686.
31. Leyssen P, De Clercq E, Neyts J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 2008; 78:9-25.
32. Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007; 51:3168-3176.
33. Gowen BB, Wong MH, Jung KH, Smee DF, Morrey JD, Furuta Y. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res 2010; 86:121-127.
34. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46:977-981.
35. Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51:845-851.
36. Gowen BB, Smee DF, Wong MH, et al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE 2008; 3:e3725.
37. Morrey JD, Taro B, Siddharthan V, et al. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 2008; 80:377-379.
38. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 2009; 53:202-209.
39. Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 2010; 107:882-887.
40. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4:406-425.
41. Zuckerkandl E, Pauling L. Evolutionary divergence and convergence in proteins. In Evolving Genes and Proteins. New York: Academic Press 1965.
42. Sun Y, Chung DH, Chu YK, Jonsson CB, Parker WB. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob Agents Chemother 2007; 51:84-88.
43. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 2003; 77:481-488.
44. Murphy ME, Kariwa H, Mizutani T, Yoshimatsu K, Arikawa J, Takashima I. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch Virol 2000; 145:1571-1582.
45. Mogford JE, Davis GE, Platts SH, Meininger GA. Vascular smooth muscle alpha v beta 3 integrin mediates arteriolar vasodilation in response to RGD peptides. Circ Res 1996; 79:821-826.
46. Platts SH, Mogford JE, Davis MJ, Meininger GA. Role of K+ channels in arteriolar vasodilation mediated by integrin interaction with RGD-containing peptide. Am J Physiol 1998; 275:H1449-H1454.
47. Buranda T, Wu Y, Perez D, et al. Recognition of decay accelerating factor and alpha(v)beta(3) by inactivated hantaviruses: Toward the development of high-throughput screening flow cytometry assays. Anal Biochem 2010; 402:151-160.
48. Krautkrämer E, Zeier M. Hantavirus causing hemorrhagic fever with renal syndrome enters from the apical surface and requires decay-accelerating factor (DAF/CD55). J Virol 2008; 82:4257-4264.
49. Chu JJ, Ng ML. Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells. J Biol Chem 2004; 279:54533-54541.
50. Elliott RM. Emerging viruses: The Bunyaviridae. Mol Med 1997; 3:572-577.
51. Hjertqvist M, Klein SL, Ahlm C, Klingstrom J. Mortality rate patterns for hemorrhagic fever with renal syndrome caused by Puumala virus. Emerg Infect Dis 2010; 16:1584-1586.
52. Monroe MC, Morzunov SP, Johnson AM, et al. Genetic diversity and distribution of Peromyscus-borne hantaviruses in North America. Emerg Infect Dis 1999; 5:75-86.
53. Plyusnin A, Morzunov SP. Virus evolution and genetic diversity of hantaviruses and their rodent hosts. Curr Top Microbiol Immunol 2001; 256:47-75.
54. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49:981-986.
55. Mendenhall M, Russell A, Juelich T, et al. T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell Culture. Antimicrob Agents Chemother 2011; 55:782-787.
56. Kim GR, McKee KT, Jr. Pathogenesis of Hantaan virus infection in suckling mice: clinical, virologic, and serologic observations. Am J Trop Med Hyg 1985; 34:388-395.
57. McKee KT, Jr., Kim GR, Green DE, Peters CJ. Hantaan virus infection in suckling mice: virologic and pathologic correlates. J Med Virol 1985; 17:107-117.